Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Piotr Koralewski"'
Autor:
Jayesh Desai, Stephane Dalle, Jermaine Coward, Daniel Brungs, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, Piotr Koralewski, Iwona Lugowska, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Philip Clingan, Rahul Ladwa, Eva Muñoz-Couselo, Henri Montaudié, Miguel-Ángel Berciano-Guerrero, Dean Laurence Harris, Susan Arnold, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Vinay Sharma, Hong Shue, Chaiyut Charoentum, Oleksandr Dudnichenko
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients ex
Externí odkaz:
https://doaj.org/article/ba79bd85b8124e27b03c0ee657e71ed1
Autor:
Robert I. Haddad, Kevin Harrington, Makoto Tahara, Robert L. Ferris, Maura Gillison, Jerome Fayette, Amaury Daste, Piotr Koralewski, Bogdan Zurawski, Miren Taberna, Nabil F. Saba, Milena Mak, Andrzej Kawecki, Gustavo Girotto, Miguel Angel Alvarez Avitia, Caroline Even, Joaquin Gabriel Reinoso Toledo, Alexander Guminski, Urs Müller-Richter, Naomi Kiyota, Mustimbo Roberts, Tariq Aziz Khan, Karen Miller-Moslin, Li Wei, Athanassios Argiris
Publikováno v:
Journal of Clinical Oncology. 41:2166-2180
PURPOSE CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570 ) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil ≤ six cycles, then cetuximab maintenance) in recurrent/metasta
Autor:
Dean Harris, Daniel Brungs, Rahul Ladwah, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, Andrey Akopov, Natalia Fadeeva, Boris Kasparov, Nadezhda Kovalenko, Vadim Kozlov, Fedor Moiseenko, Vasiliy Oschepkov, Piotr Koralewski, Dariusz Kowalski, Iwona Lugowska, Chaiyut Charoentumn, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Philip Clingan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/115fbf3202dd41a198c2223d3da6fcbc
Autor:
Cristiane Bergerot, Sun Young Rha, Sumanta Pal, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Jae Lyun Lee, Kaisa Sunela, Tudor Ciuleanu, Daniel Heng, Hilary Glen, Jinyi Wang, Lee Bennett, Janice Pan, Karen O’Hara, Javier Puente
Publikováno v:
The Oncologist. 28:59-71
Background Preserving health-related quality of life (HRQOL) is an important goal during renal cell carcinoma treatment. We report HRQOL outcomes from a phase II trial (NCT03173560). Patients and Methods HRQOL data were collected during a multicenter
Autor:
Stefano Stabile, Constantin Volovat, Piotr Koralewski, Krassimir Koynov, Iulian Bobe, Adina Croitoru, Juneko E. Grilley Olson, Tudor-Eliade Ciuleanu, Giulio Cerea, Atsushi Osada, Simona Ruxandra Volovat
Publikováno v:
Oncotarget
NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve selective distribution to tumors. Here, in the Phase II portion of this study, the activity,
Autor:
Sumanta K. Pal, Javier Puente, Daniel Y.C. Heng, Hilary Glen, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Tudor Ciuleanu, Jae Lyun Lee, Kaisa Sunela, Karen O'Hara, Terri A. Binder, Lixian Peng, Alan D. Smith, Sun Young Rha
Publikováno v:
European urology. 82(3)
Background: Lenvatinib (18 mg) plus everolimus (5 mg) is approved for patients with advanced renal cell carcinoma (RCC) after one or more prior antiangiogenic therapies. Objective: To assess whether a lower starting dose of lenvatinib has comparable
Autor:
Boris Kasparov, Philip Clingan, Natalia Fadeeva, Andrey Akopov, Margaret McGrath, Vasiliy Oschepkov, Vadim Kozlov, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, D. Harris, Fedor Moiseenko, Andrea Tazbirkova, Piotr Koralewski, Chaiyut Charoentumn, Iwona Lugowska, Nadezhda Kovalenko, Dariusz Kowalski, Daniel Brungs, Andrew Mant, Rahul Ladwah
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Cosibelimab is a high affinity, fully-human IgG1 monoclonal antibody that directly binds to programmed death ligand-1 (PD-L1) and blocks its interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors to restore an anti-tumo
Autor:
Francis Parnis, Jae-Lyun Lee, Kaisa Sunela, Cristiane Decat Bergerot, Janice Pan, Hilary Glen, Karen O'Hara, Sumanta K. Pal, Sun Young Rha, Javier Puente, Lee Bennett, Piotr Koralewski, Jinyi Wang, Tudor Ciuleanu, Daniel Castellano, Daniil Stroyakovskiy, Boris Alekseev, Daniel Y.C. Heng
Publikováno v:
Journal of Clinical Oncology. 39:314-314
314 Background: Renal cell carcinoma (RCC) is the most common type of kidney cancer, constituting 80% to 85% of primary renal neoplasms. Preserving health-related quality of life (HRQOL) is an important goal during RCC treatment, but HRQOL analyses i
Autor:
Tudor Ciuleanu, Terri A. Binder, Karen O'Hara, Hilary Glen, Lixian Peng, Daniel Y.C. Heng, Boris Alekseev, Daniil Stroyakovskiy, Daniel Castellano, Alan D. Smith, Piotr Koralewski, Francis Parnis, Jae-Lyun Lee, Kaisa Sunela, Sumanta K. Pal, Sun Young Rha, Javier Puente
Publikováno v:
Journal of Clinical Oncology. 39:307-307
307 Background: LEN 18 mg + EVE 5 mg is approved for advanced RCC following anti-angiogenic therapy. Study 218 was a phase II study evaluating LEN 14 mg vs LEN 18 mg, both in combination with EVE 5 mg, for the treatment of clear cell RCC following tr
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
Autor:
Cezary Szczylik, Mayer Fishman, Yu Nien Sun, Andrzej Deptała, Piotr Koralewski, Karolyn Kracht, Bernard Escudier, Rodryg Ramlau, Brian I. Rini, Michael Bass, Luc Dirix, Alain Ravaud, Wojciech Rogowski, Markus Puhlmann, Nizar M. Tannir, Piotr Tomczak
Publikováno v:
Cancer. 118:6152-6161
Upregulation of proangiogenic factors in response to inactivation of the von Hippel-Lindau (VHL) gene is a critical component in the development and progression of clear cell renal cell carcinoma (RCC).1 Several inhibitors of the vascular endothelial